Amendment to Cardlytics, Inc. 2022 Inducement Plan Increasing Share Reserve
Contract Categories:
Business Finance
›
Modification Agreements
Summary
Cardlytics, Inc. has amended its 2022 Inducement Plan to increase the number of shares of common stock reserved for issuance from 1,500,000 to 1,850,000. All other terms of the plan remain unchanged. This amendment was executed by the company's Chief Executive Officer on January 18, 2023.
EX-10.45 6 cdlx_formx10-kx2022xex1045.htm EX-10.45 Document
Exhibit 10.45
AMENDMENT TO
CARDLYTICS, INC.
2022 INDUCEMENT PLAN
A. Cardlytics, Inc., a corporation organized under the laws of the State of Delaware, (the “Company”) established the Company’s 2022 Inducement Plan (the “Plan”);
B. The Plan currently provides for 1,500,000 shares of Common Stock to be reserved for issuance under the Plan; and
C. The Company now wishes to amend the Plan to increase the number of shares of Common Stock reserved for issuance under the Plan to an aggregate of 1,850,000 shares.
Effective immediately, the Plan is amended as follows:
1. The reference to “1,500,000 shares” in Section 3(a) of the Plan is hereby amended to reference “1,850,000 shares”.
2. In all other respects, the Plan will remain the same.
Exhibit 10.45
IN WITNESS WHEREOF, the Company has caused this Amendment to be executed as of January 18, 2023.
| CARDLYTICS, INC. | ||
By: /s/ Karim Temsamani | ||
Karim Temsamani | ||
| Chief Executive Officer | ||
